<p>Evotec AG 最近的财报电话会议描绘了在充满挑战的环境中展现出的韧性。尽管公司在药物发现与临床前开发（D&amp;PD）领域面临重大阻力，整体收入也有所下降，但仍有亮点。值得注意的是，生物制药部门表现出强劲的增长，与 Sandoz 的战略合作伙伴关系以及有效的成本削减策略，尽管当前面临困难，仍然暗示了乐观的未来前景。</p>
<h2>Just-Evotec 生物制药增长</h2>
<p>Just-Evotec 生物制药部门表现强劲，收入达到 1.432 亿欧元，比去年增长 11%。这一增长进一步得到了来自非 Sandoz 和非国防部（DoD）客户的收入在前九个月内增长 105% 的显著支持。</p>
<h2>与 Sandoz 的变革性交易</h2>
<p>Evotec 与 Sandoz 签署的变革性交易是一个关键发展，预计将在未来几年解锁超过 6.5 亿美元的付款。这包括一笔 3.5 亿美元的预付款和潜在的中期收入超过 3 亿美元，突显了这一合作伙伴关系的战略重要性。</p>
<h2>资产管道进展</h2>
<p>Evotec 的资产管道进展令人鼓舞，预计到 2026 年，将有多达四种分子来自其合作的资产管道进入 II 期临床研究。这一进展强调了公司对创新和长期增长的承诺。</p>
<h2>成本削减举措</h2>
<p>Evotec 在成本削减举措上取得了显著进展，已经超前于计划。公司承诺到 2025 年削减 6000 万欧元的成本，并致力于实现额外 5000 万欧元的成本节约和生产力措施。</p>
<h2>集团收入下降</h2>
<p>前九个月集团收入为 5.351 亿欧元，同比下降 7%。这一下降主要归因于早期药物发现市场的疲软，影响了 D&amp;PD 部门。</p>
<h2>D&amp;PD 业务挑战</h2>
<p>D&amp;PD 部门面临 12% 的收入下降，主要是由于早期药物发现市场的持续疲软以及生物技术领域不利的风险投资融资环境，影响了 Evotec 的交易服务业务。</p>
<h2>负 EBITDA</h2>
<p>调整后的集团 EBITDA 为负 1690 万欧元，主要是由于 D&amp;PD 收入低于预期和固定成本基础，突显了公司面临的财务挑战。</p>
<h2>风险投资融资环境</h2>
<p>生物技术领域的风险投资融资环境仍然不利，影响了早期药物发现市场，并对 Evotec 的交易服务业务造成影响，增加了 D&amp;PD 部门的挑战。</p>
<h2>前瞻性指导</h2>
<p>尽管面临挑战，Evotec 对 2025 年保持乐观展望，预计集团收入在 7.6 亿至 8 亿欧元之间，调整后的 EBITDA 在 3000 万至 5000 万欧元之间。公司预计中期增长为 8% 至 12%，EBITDA 利润率超过 20%。此外，Sandoz 交易预计将为与 10 种生物仿制药相关的特许权使用费流产生可观收入。</p>
<p>总之，Evotec AG 的财报电话会议反映出公司在艰难环境中进行战略前瞻的努力。尽管 D&amp;PD 部门仍面临挑战，但生物制药部门的增长、战略合作伙伴关系和成本削减努力为乐观提供了基础。投资者和利益相关者可以期待 Evotec 在未来几年继续展现韧性和战略进展。</p>

<p>Evotec AG 的财报电话会议强调了在挑战中展现出的韧性，收入下降了 7%，降至 5.351 亿欧元，主要是由于药物发现与临床前开发（D&PD）部门的困难。然而，生物制剂部门增长了 11%，达到 1.432 亿欧元，得益于与 Sandoz 的一项重大交易，预计将带来超过 6.5 亿美元的收益。成本削减措施进展超前，目标是到 2025 年实现 6000 万欧元的节省。尽管面临当前的挑战，Evotec 预计集团收入将在 7.6 亿至 8 亿欧元之间，并预计 2025 年将实现正 EBITDA，显示出战略前进的方向</p>

<p>Evotec AG’s recent earnings call painted a picture of resilience amidst a challenging environment. While the company faced significant headwinds in its Drug Discovery &amp; Preclinical Development (D&amp;PD) segment and an overall decline in revenue, there were bright spots. Notably, the Biologics segment demonstrated robust growth, and strategic partnerships, such as the one with Sandoz, alongside effective cost reduction strategies, suggest an optimistic future outlook despite current hurdles.</p>
<div class="lb-trans"><p>Evotec AG 最近的财报电话会议描绘了在充满挑战的环境中展现出的韧性。尽管公司在药物发现与临床前开发（D&amp;PD）领域面临重大阻力，整体收入也有所下降，但仍有亮点。值得注意的是，生物制药部门表现出强劲的增长，与 Sandoz 的战略合作伙伴关系以及有效的成本削减策略，尽管当前面临困难，仍然暗示了乐观的未来前景。</p>
</div><h2>Just-Evotec Biologics Growth</h2>
<div class="lb-trans"><h2>Just-Evotec 生物制药增长</h2>
</div><p>The Just-Evotec Biologics segment emerged as a strong performer, with revenues reaching EUR 143.2 million, marking an 11% increase from the previous year. This growth was further underscored by a remarkable 105% rise in revenues from non-Sandoz and non-Department of Defense (DoD) customers in the first nine months of the year.</p>
<div class="lb-trans"><p>Just-Evotec 生物制药部门表现强劲，收入达到 1.432 亿欧元，比去年增长 11%。这一增长进一步得到了来自非 Sandoz 和非国防部（DoD）客户的收入在前九个月内增长 105% 的显著支持。</p>
</div><h2>Transformational Deal with Sandoz</h2>
<div class="lb-trans"><h2>与 Sandoz 的变革性交易</h2>
</div><p>Evotec’s signing of a transformational deal with Sandoz is a pivotal development, expected to unlock payments exceeding $650 million in the coming years. This includes a substantial $350 million upfront payment and potential mid-term revenues surpassing $300 million, highlighting the strategic importance of this partnership.</p>
<div class="lb-trans"><p>Evotec 与 Sandoz 签署的变革性交易是一个关键发展，预计将在未来几年解锁超过 6.5 亿美元的付款。这包括一笔 3.5 亿美元的预付款和潜在的中期收入超过 3 亿美元，突显了这一合作伙伴关系的战略重要性。</p>
</div><h2>Asset Pipeline Progression</h2>
<div class="lb-trans"><h2>资产管道进展</h2>
</div><p>The progression of Evotec’s asset pipeline is promising, with expectations for up to four molecules from their partnered asset pipeline to enter Phase II clinical studies by 2026. This advancement underscores the company’s commitment to innovation and long-term growth.</p>
<div class="lb-trans"><p>Evotec 的资产管道进展令人鼓舞，预计到 2026 年，将有多达四种分子来自其合作的资产管道进入 II 期临床研究。这一进展强调了公司对创新和长期增长的承诺。</p>
</div><h2>Cost Reduction Initiatives</h2>
<div class="lb-trans"><h2>成本削减举措</h2>
</div><p>Evotec is making significant strides in its cost reduction initiatives, already ahead of its plan. The company has committed to a EUR 60 million cost reduction by 2025 and is working towards delivering an additional EUR 50 million in cost savings and productivity measures.</p>
<div class="lb-trans"><p>Evotec 在成本削减举措上取得了显著进展，已经超前于计划。公司承诺到 2025 年削减 6000 万欧元的成本，并致力于实现额外 5000 万欧元的成本节约和生产力措施。</p>
</div><h2>Group Revenue Decline</h2>
<div class="lb-trans"><h2>集团收入下降</h2>
</div><p>Group revenues for the first nine months stood at EUR 535.1 million, reflecting a 7% decline compared to the previous year. This decrease is primarily attributed to softness in the early drug discovery market, affecting the D&amp;PD segment.</p>
<div class="lb-trans"><p>前九个月集团收入为 5.351 亿欧元，同比下降 7%。这一下降主要归因于早期药物发现市场的疲软，影响了 D&amp;PD 部门。</p>
</div><h2>D&amp;PD Business Challenges</h2>
<div class="lb-trans"><h2>D&amp;PD 业务挑战</h2>
</div><p>The D&amp;PD segment faced a 12% revenue decline, driven by continued softness in the early drug discovery market and unfavorable venture capital funding conditions for biotech, impacting Evotec’s transactional service business.</p>
<div class="lb-trans"><p>D&amp;PD 部门面临 12% 的收入下降，主要是由于早期药物发现市场的持续疲软以及生物技术领域不利的风险投资融资环境，影响了 Evotec 的交易服务业务。</p>
</div><h2>Negative EBITDA</h2>
<div class="lb-trans"><h2>负 EBITDA</h2>
</div><p>The adjusted Group EBITDA was negative EUR 16.9 million, a result of weaker than expected D&amp;PD revenues and a fixed cost base, highlighting the financial challenges faced by the company.</p>
<div class="lb-trans"><p>调整后的集团 EBITDA 为负 1690 万欧元，主要是由于 D&amp;PD 收入低于预期和固定成本基础，突显了公司面临的财务挑战。</p>
</div><h2>VC Funding Environment</h2>
<div class="lb-trans"><h2>风险投资融资环境</h2>
</div><p>The venture capital funding environment for biotech remains unfavorable, impacting the early drug discovery market and affecting Evotec’s transactional service business, adding to the challenges in the D&amp;PD segment.</p>
<div class="lb-trans"><p>生物技术领域的风险投资融资环境仍然不利，影响了早期药物发现市场，并对 Evotec 的交易服务业务造成影响，增加了 D&amp;PD 部门的挑战。</p>
</div><h2>Forward-Looking Guidance</h2>
<div class="lb-trans"><h2>前瞻性指导</h2>
</div><p>Despite the challenges, Evotec maintains a positive outlook for 2025, with guidance for group revenues between EUR 760 million to EUR 800 million and adjusted EBITDA ranging from EUR 30 million to EUR 50 million. The company anticipates mid-term growth of 8% to 12% and EBITDA margins above 20%. Additionally, the Sandoz deal is expected to generate significant revenues from royalty streams related to 10 biosimilars.</p>
<div class="lb-trans"><p>尽管面临挑战，Evotec 对 2025 年保持乐观展望，预计集团收入在 7.6 亿至 8 亿欧元之间，调整后的 EBITDA 在 3000 万至 5000 万欧元之间。公司预计中期增长为 8% 至 12%，EBITDA 利润率超过 20%。此外，Sandoz 交易预计将为与 10 种生物仿制药相关的特许权使用费流产生可观收入。</p>
</div><p>In summary, Evotec AG’s earnings call reflects a company navigating through a tough landscape with strategic foresight. While challenges persist, particularly in the D&amp;PD segment, the growth in the Biologics segment, strategic partnerships, and cost reduction efforts provide a foundation for optimism. Investors and stakeholders can look forward to Evotec’s continued resilience and strategic advancements in the coming years.</p>
<div class="lb-trans"><p>总之，Evotec AG 的财报电话会议反映出公司在艰难环境中进行战略前瞻的努力。尽管 D&amp;PD 部门仍面临挑战，但生物制药部门的增长、战略合作伙伴关系和成本削减努力为乐观提供了基础。投资者和利益相关者可以期待 Evotec 在未来几年继续展现韧性和战略进展。</p>
</div>

Evotec AG 财报电话会议：在挑战中展现出韧性